Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer

Transl Lung Cancer Res. 2023 Jan 31;12(1):6-10. doi: 10.21037/tlcr-22-872. Epub 2022 Dec 26.

Yuji Uehara^{1

2}, Taiki Hakozaki^{1

3}

¹ Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
² Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
³ Graduate School of Advanced Science and Engineering, Faculty of Science and Engineering, Waseda University, Tokyo, Japan.

No abstract available

Keywords: Immune checkpoint inhibitor (ICI); biomarker; gene rearrangement; non-small cell lung cancer (NSCLC); prognosis.

Publication types